Biotech Values

[jq1234]

VRTX no longer invest in HCV R&D!

[Applause]

Vertex today announced that it has amended the terms of its agreement with Alios BioPharma regarding the development and commercialization of the nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135. Based on the revised agreement and the rapid changes in the hepatitis C treatment landscape following the introduction of new oral therapies, Vertex plans to out-license VX-135 and to end further investment into research and development efforts in hepatitis C.

1Q2014 Result PR:

http://investors.vrtx.com/releasedetail.cfm?ReleaseID=844664